Market research
CW9.F Compugen Ltd
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 432M
- P/E ratio
- Not available
- Analyst target
- 20.86
- Dividend yield
- 0.0%
- Beta
- 2.65
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 432M
- P/E ratio
- Not available
- Analyst target
- 20.86
- Dividend yield
- 0.0%
- Beta
- 2.65
About
About Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CW9.F discussion.
5 years, 4 months ago
Compugen Ltd is currently in a long term downtrend where the price is trading 32.5% below its 200 day moving average.
From a valuation standpoint, the stock is 73.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 354.7.
Compugen Ltd's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has dropped by 32.5% to $-9M since the same quarter in the previous year.
Based on the above factors, Compugen Ltd gets an overall score of 2/5.